{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=18", "query": { "intervention": "trastuzumab", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T12:51:02.719Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03529110", "title": "DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Ado-trastuzumab emtansine (T-DM1)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 524, "start_date": "2018-08-09", "completion_date": "2026-08-31", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 28, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03529110" }, { "nct_id": "NCT00387907", "title": "Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "larotaxel (XRP9881)", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 6, "start_date": "2006-10", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2016-05-05", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 1, "location_summary": "Malvern, Pennsylvania", "locations": [ { "city": "Malvern", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387907" }, { "nct_id": "NCT07015697", "title": "A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-07-17", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 6, "location_summary": "Newport Beach, California • Atlanta, Georgia • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Maumee", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07015697" }, { "nct_id": "NCT00927589", "title": "A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2009-07", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2015-12-10", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00927589" }, { "nct_id": "NCT00191373", "title": "A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Cancer of the Breast", "Breast Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 66, "start_date": "2002-03", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2007-09-12", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 13, "location_summary": "Hot Springs, Arkansas • Pine Bluff, Arkansas • Redding, California + 10 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Redding", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00191373" }, { "nct_id": "NCT01008150", "title": "Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2010-10", "completion_date": "2016-11-25", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 30, "location_summary": "Loma Linda, California • San Diego, California • Denver, Colorado + 25 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008150" }, { "nct_id": "NCT04510285", "title": "A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Tumors", "Gastric Cancer", "Gastric Tumor", "Esophageal Cancer", "Esophageal Neoplasms", "Esophageal Tumor", "GastroEsophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Tumor", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-08-10", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510285" }, { "nct_id": "NCT00833963", "title": "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Pregnancy" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Ado-Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2009-01-14", "completion_date": "2017-04-13", "has_results": false, "last_update_posted_date": "2019-05-16", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833963" }, { "nct_id": "NCT01160211", "title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 369, "start_date": "2011-05-05", "completion_date": "2022-06-06", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 4, "location_summary": "Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160211" }, { "nct_id": "NCT07619521", "title": "Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2027-06-01", "completion_date": "2028-09-08", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T12:51:02.719Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Pittsburgh, Pennsylvania", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619521" } ] }